Antiviral therapy prolongs survival in immune tolerant hepatitis B patients

(European Association for the Study of the Liver) A new study, presented today at The International Liver Congress 2016 in Barcelona Spain, demonstrates that the use of antiviral therapy for patients in the immune tolerant phase of hepatitis B (HBV) prolongs overall survival and reduces the risk of the most common form of liver cancer (Hepatocellular Carcinoma, HCC) and scarring of the liver (cirrhosis).

http://www.eurekalert.org/pub_releases/2016-04/eaft-atp040816.php

Source: EurekAlert! - Infectious and Emerging Diseases - April 15, 2016 Category: Infectious Diseases Source Type: news